US Patent Issued to ZHEJIANG WENDA PHARMA TECHNOLOGY on June 16 for "Heterocyclic compound as TYK2 pseudokinase domain inhibitor, synthetic method, and use" (Chinese Inventor)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,655,108, issued on June 16, was assigned to ZHEJIANG WENDA PHARMA TECHNOLOGY LTD. (Hangzhou, China).

"Heterocyclic compound as TYK2 pseudokinase domain inhibitor, synthetic method, and use" was invented by Nenghui Wang (Ningbo, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a heterocyclic compound as a TYK2 pseudokinase (JH2) domain inhibitor, a synthetic method, and use. In particular, the present invention provides a heterocyclic compound as represented by formula I, or a pharmaceutically acceptable salt thereof, wherein groups are as defined in the text. The heterocyclic compound in the present invention has excel...